Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 139

1.

P16INK4a expression in undifferentiated carcinoma of the uterus does not exclude its endometrial origin.

Saad RS, Mashhour M, Noftech-Mozes S, Ismiil N, Dubé V, Ghorab Z, Faragalla H, Khalifa MA.

Int J Gynecol Pathol. 2012 Jan;31(1):57-65. doi: 10.1097/PGP.0b013e318223118a.

PMID:
22123724
[PubMed - indexed for MEDLINE]
2.

Utility of p16 expression for distinction of uterine serous carcinomas from endometrial endometrioid and endocervical adenocarcinomas: immunohistochemical analysis of 201 cases.

Yemelyanova A, Ji H, Shih IeM, Wang TL, Wu LS, Ronnett BM.

Am J Surg Pathol. 2009 Oct;33(10):1504-14. doi: 10.1097/PAS.0b013e3181ac35f5.

PMID:
19623034
[PubMed - indexed for MEDLINE]
3.
4.

A panel of immunohistochemical stains, including carcinoembryonic antigen, vimentin, and estrogen receptor, aids the distinction between primary endometrial and endocervical adenocarcinomas.

McCluggage WG, Sumathi VP, McBride HA, Patterson A.

Int J Gynecol Pathol. 2002 Jan;21(1):11-5.

PMID:
11781517
[PubMed - indexed for MEDLINE]
5.

A panel of 3 markers including p16, ProExC, or HPV ISH is optimal for distinguishing between primary endometrial and endocervical adenocarcinomas.

Kong CS, Beck AH, Longacre TA.

Am J Surg Pathol. 2010 Jul;34(7):915-26. doi: 10.1097/PAS.0b013e3181e3291e.

PMID:
20534993
[PubMed - indexed for MEDLINE]
6.

Immunophenotypic diversity of endometrial adenocarcinomas: implications for differential diagnosis.

Reid-Nicholson M, Iyengar P, Hummer AJ, Linkov I, Asher M, Soslow RA.

Mod Pathol. 2006 Aug;19(8):1091-100. Epub 2006 Apr 28.

PMID:
16648864
[PubMed - indexed for MEDLINE]
Free Article
7.

p16 immunoreactivity may assist in the distinction between endometrial and endocervical adenocarcinoma.

McCluggage WG, Jenkins D.

Int J Gynecol Pathol. 2003 Jul;22(3):231-5.

PMID:
12819388
[PubMed - indexed for MEDLINE]
9.

p16 expression in primary ovarian mucinous and endometrioid tumors and metastatic adenocarcinomas in the ovary: utility for identification of metastatic HPV-related endocervical adenocarcinomas.

Vang R, Gown AM, Farinola M, Barry TS, Wheeler DT, Yemelyanova A, Seidman JD, Judson K, Ronnett BM.

Am J Surg Pathol. 2007 May;31(5):653-63.

PMID:
17460447
[PubMed - indexed for MEDLINE]
10.

Immunohistochemistry and HPV in situ hybridization in pathologic distinction between endocervical and endometrial adenocarcinoma: a comparative tissue microarray study of 76 tumors.

Jones MW, Onisko A, Dabbs DJ, Elishaev E, Chiosea S, Bhargava R.

Int J Gynecol Cancer. 2013 Feb;23(2):380-4. doi: 10.1097/IGC.0b013e31825cc8ee.

PMID:
23318908
[PubMed - indexed for MEDLINE]
11.

Intestinal-type cervical adenocarcinoma in situ and adenocarcinoma exhibit a partial enteric immunophenotype with consistent expression of CDX2.

McCluggage WG, Shah R, Connolly LE, McBride HA.

Int J Gynecol Pathol. 2008 Jan;27(1):92-100.

PMID:
18156982
[PubMed - indexed for MEDLINE]
12.

p16 expression in the female genital tract and its value in diagnosis.

O'Neill CJ, McCluggage WG.

Adv Anat Pathol. 2006 Jan;13(1):8-15. Review.

PMID:
16462152
[PubMed - indexed for MEDLINE]
13.

Distinguishing between primary endocervical and endometrial adenocarcinomas: is a 2-marker (Vim/CEA) panel enough?

Liao CL, Hsu JD, Lee MY, Kok LF, Li YJ, Wang PH, Yao CC, Han CP.

Virchows Arch. 2010 Apr;456(4):377-86. doi: 10.1007/s00428-010-0892-x. Epub 2010 Mar 11.

PMID:
20221633
[PubMed - indexed for MEDLINE]
14.

Distinction of endocervical and endometrial adenocarcinomas: immunohistochemical p16 expression correlated with human papillomavirus (HPV) DNA detection.

Ansari-Lari MA, Staebler A, Zaino RJ, Shah KV, Ronnett BM.

Am J Surg Pathol. 2004 Feb;28(2):160-7.

PMID:
15043304
[PubMed - indexed for MEDLINE]
15.

Endometrial endometrioid adenocarcinoma of the uterine corpus involving the cervix: some cases probably represent independent primaries.

Jiang L, Malpica A, Deavers MT, Guo M, Villa LL, Nuovo G, Merino MJ, Silva EG.

Int J Gynecol Pathol. 2010 Mar;29(2):146-56. doi: 10.1097/PGP.0b013e3181b8e951.

PMID:
20173500
[PubMed - indexed for MEDLINE]
16.

p16 INK4 and CEA can be mutually exchanged with confidence between both relevant three-marker panels (ER/Vim/CEA and ER/Vim/p16 INK4) in distinguishing primary endometrial adenocarcinomas from endocervical adenocarcinomas in a tissue microarray study.

Han CP, Lee MY, Tyan YS, Kok LF, Yao CC, Wang PH, Hsu JD, Tseng SW.

Virchows Arch. 2009 Oct;455(4):353-61. doi: 10.1007/s00428-009-0826-7. Epub 2009 Sep 9.

PMID:
19763614
[PubMed - indexed for MEDLINE]
17.

ProExC is a novel marker for distinguishing between primary endometrial and endocervical adenocarcinomas.

Esheba GE.

J Egypt Natl Canc Inst. 2013 Jun;25(2):87-93. doi: 10.1016/j.jnci.2013.01.005. Epub 2013 Feb 14.

PMID:
23719407
[PubMed - indexed for MEDLINE]
Free Article
18.

[Value of ER, VIM, CEA and p16 detection in the diagnosis and differential diagnosis of primary endocervical and endometrial adenocarcinomas].

Hu WW, Tao JH, Li GM, Xu X, Yang XM.

Nan Fang Yi Ke Da Xue Xue Bao. 2010 Mar;30(3):526-8, 531. Chinese.

PMID:
20335127
[PubMed - indexed for MEDLINE]
Free Article
19.

New developments in endocervical glandular lesions.

McCluggage WG.

Histopathology. 2013 Jan;62(1):138-60. doi: 10.1111/his.12012. Epub 2012 Nov 8. Review.

PMID:
23134447
[PubMed - indexed for MEDLINE]
20.

Adding the p16(INK4a) marker to the traditional 3-marker (ER/Vim/CEA) panel engenders no supplemental benefit in distinguishing between primary endocervical and endometrial adenocarcinomas in a tissue microarray study.

Han CP, Lee MY, Kok LF, Ruan A, Wu TS, Cheng YW, Tyan YS, Lin CY.

Int J Gynecol Pathol. 2009 Sep;28(5):489-96. doi: 10.1097/PGP.0b013e31819e8ab4.

PMID:
19696622
[PubMed - indexed for MEDLINE]
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk